Genmab A/S to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on March 22, 2018
21 Mar, 2018, 11:02 ET
Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event
COPENHAGEN, Denmark, March 21, 2018 /CNW/ -- Genmab A/S (CPH: GEN.CO, OTC Pink: GMXAY), focused on the creation and development of differentiated antibody therapeutics for the treatment of cancer, today announced that Genmab's Senior Vice President, IR & Communications, Rachel Curtis Gravesen, will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on March 22, 2018. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.
DATE: March 22nd, 2018
TIME: 12.30pm ET
This will be a live, interactive online event where investors are invited to ask international companies their questions in real-time and to download a company's information in their "virtual trade booth" in the Exhibits section. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
Participation is free of charge.
It is recommended that investors pre-register to save time and receive event updates.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
SOURCE Genmab A/S
For further information: Genmab A/S, Rachel Curtis Gravesen, Senior Vice President, IR & Communications, [email protected], +45 33 44 77 20, http://www.genmab.com
Share this article